Agenus Inc. reported second-quarter 2026 financial results and announced the acceleration of its Phase 3 ROBBIN trial for neoadjuvant botensilimab plus balstilimab in microsatellite-stable colon cancer, with first patient dosing expected in Q1 2027. The company completed an oversubscribed $85 million private placement in July 2026, which includes warrants potentially providing up to $255 million more if fully exercised; these funds support operations through late 2031. Total revenue for the quarter was $34.5 million, including $6.4 million from pre-commercial product access programs and $28.1 million in non-cash royalty revenue. Agenus also discontinued funding for the BATTMAN Phase 3 trial following financing prioritization. Agenus Inc. is a clinical-stage immuno-oncology company developing antibody-based cancer immunotherapies.
